2026. Frontline DNA-Repair Inhibition as Maintenance in High-Risk Ovarian Carcinoma. International Journal of Clinical Research and Medical Sciences. 1, 3 (Oct. 2026). DOI:https://doi.org/10.67231/4gks8p50.